Clinical Trial Detail

NCT ID NCT03783078
Title Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

Merkel cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult child senior

No variant requirements are available.